Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of AD-213-A vs AD-2131 in Healthy Adults
NCT04690868Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-213-A in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area Under the Concentration-time Curve Over the Dosing Interval at Day 17 and Integrated Gastric Acidity (% Decrease from Baseline) at Day 17. Started Oct 2021; status: completed.
02
Drugs
AD-213-A
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04690868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690868.